Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib

A 68-year-old man with hepatocellular carcinoma (HCC) visited his previous hospital due to abdominal pain and was diagnosed with ruptured HCC. Before visiting our hospital, he underwent HCC treatment at his previous hospital, but his tumors did not improve. Although he started treatment with sorafen...

Full description

Saved in:
Bibliographic Details
Published inInternal Medicine Vol. 60; no. 13; pp. 2047 - 2053
Main Authors Yamaoka, Kenji, Kawaoka, Tomokazu, Aikata, Hiroshi, Ando, Yuwa, Kosaka, Yumi, Suehiro, Yosuke, Fujii, Yasutomo, Uchikawa, Shinsuke, Morio, Kei, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Yamauchi, Masami, Tsuge, Masataka, Hiramatsu, Akira, Imamura, Michio, Takahashi, Shoichi, Saeki, Yoshihiro, Kuroda, Shintaro, Kobayashi, Tsuyoshi, Ohdan, Hideki, Miyata, Yoshihiro, Okada, Morihito, Chayama, Kazuaki
Format Journal Article
LanguageEnglish
Published Tokyo The Japanese Society of Internal Medicine 01.07.2021
Japan Science and Technology Agency
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:A 68-year-old man with hepatocellular carcinoma (HCC) visited his previous hospital due to abdominal pain and was diagnosed with ruptured HCC. Before visiting our hospital, he underwent HCC treatment at his previous hospital, but his tumors did not improve. Although he started treatment with sorafenib, the tumors rapidly grew. Subsequently, regorafenib was given, and the tumors shrank. After 22 months being treated with regorafenib, HCC reoccurred, with a new lung metastasis and a contrast-enhanced nodule on the peritoneal dissemination appearing. He underwent conversion surgery and survived for 4.5 years after his HCC was diagnosed.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
Correspondence to Dr. Hiroshi Aikata, aikata@hiroshima-u.ac.jp
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.5870-20